Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.
- 1Medical Diagnostic Center, University Clinic for Innovative Patient Pathways, Regional Hospital Central Jutland, Viborg, Denmark; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark. Electronic address: [email protected].
- 2Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.
- 3Institute of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland.
Abstract
Background
In the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial, treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) in patients with cardiovascular disease, overweight or obesity, and no diabetes.Objectives
The purpose of this study was to estimate cardiovascular risk in first-time myocardial infarction (MI) patients meeting the SELECT-eligibility criteria and the preventive potential for treatment with semaglutide.Methods
We conducted an observational cohort study applying the SELECT trial's inclusion and exclusion criteria to patients with first-time MI recorded between 2010 and 2021 in the Western Denmark Heart Registry. Five-year incidence of second MI, MACE, and all-cause death was estimated for SELECT-eligible patients with a body mass index (BMI) ≥27 kg/m². In an assumption-dependent scenario analysis the preventive potential for semaglutide was estimated as the postponement of MACE incidence.Results
In 21,777 first-time MI patients without diabetes, 10,768 patients were SELECT-eligible with BMI ≥27 kg/m². Median age at first-time MI was 65 years for the SELECT-eligible MI patients and 69 years for normal-weight (BMI 20-26 kg/m²) comparisons. Five-year incidence of second MI (n = 544), MACE (n = 975), and all-cause death (n = 914) was 5.9% (95% CI: 5.4%-6.4%), 10.7% (95% CI: 10.1%-11.4%), and 10.3% (95% CI: 9.7%-11.0%) in SELECT-eligible MI patients, respectively. Among these, treatment with semaglutide was estimated to postpone a 5% MACE incidence by 12 months.Conclusions
In SELECT-eligible first-time MI patients with overweight or obesity and no diabetes, the cardiovascular risk was substantial with 1 in 10 having a MACE event within 5 years after first-time MI. Based on the SELECT trial results, semaglutide may markedly postpone MACE incidence in these patients.
Related
- Independent and joint associations of reported household chemical product use and overweight/obesity with cardiovascular disease among older adults in China: a national cross-sectional study.
- Influence of yoga on the epigenetics of obesity: a study on its short- and medium-term benefits in the treatment of patients with severe/morbid obesity eligible for bariatric surgery
- Insulin Intensification and Simplification Strategies in Patients with Type 2 Diabetes and Overweight or Obesity: A Scoping Review
- Prevalence of microalbuminuria in type 2 diabetes mellitus patients and its association to overweight and obesity in Aljouf, Saudi Arabia
- Association between metabolic overweight/obesity phenotypes and readmission risk in patients with Immune Thrombocytopenia (ITP): a national retrospective study.
BibTeX
@article{hansen2026cardiovascular,
title = {{Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.}},
author = {Malene K Hansen and Kevin K W Olesen and Christine Gyldenkerne and Nina Stødkilde-Jørgensen and Malene H Andersen and Naveed Sattar and Michael Maeng},
journal = {JACC. Advances},
year = {2026},
month = oct,
doi = {10.1016/j.jacadv.2026.103311},
url = {https://europepmc.org/article/MED/42858539},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Cardiovascular Risk in SELECT-Eligible MI Patients With Overweight or Obesity: The Western Denmark Heart Registry.
AU - Malene K Hansen
AU - Kevin K W Olesen
AU - Christine Gyldenkerne
AU - Nina Stødkilde-Jørgensen
AU - Malene H Andersen
AU - Naveed Sattar
AU - Michael Maeng
PY - 2026
DA - 2026/10/09
JO - JACC. Advances
DO - 10.1016/j.jacadv.2026.103311
UR - https://europepmc.org/article/MED/42858539
AB - Background In the SELECT (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity) trial, treatment with semaglutide reduced the risk of major adverse cardiovascular events (MACE) in patients with cardiovascular disease, overweight or obesity, and no diabetes.Objectives The purpose of this study was to estimate cardiovascular risk in first-time myocardial infarction (MI) patients meeting the SELECT-eligibility criteria and the preventive potential for treatment with semaglutide.Methods We conducted an observational cohort study applying the SELECT trial's inclusion and exclusion criteria to patients with first-time MI recorded between 2010 and 2021 in the Western Denmark Heart Registry. Five-year incidence of second MI, MACE, and all-cause death was estimated for SELECT-eligible patients with a body mass index (BMI) ≥27 kg/m². In an assumption-dependent scenario analysis the preventive potential for semaglutide was estimated as the postponement of MACE incidence.Results In 21,777 first-time MI patients without diabetes, 10,768 patients were SELECT-eligible with BMI ≥27 kg/m². Median age at first-time MI was 65 years for the SELECT-eligible MI patients and 69 years for normal-weight (BMI 20-26 kg/m²) comparisons. Five-year incidence of second MI (n = 544), MACE (n = 975), and all-cause death (n = 914) was 5.9% (95% CI: 5.4%-6.4%), 10.7% (95% CI: 10.1%-11.4%), and 10.3% (95% CI: 9.7%-11.0%) in SELECT-eligible MI patients, respectively. Among these, treatment with semaglutide was estimated to postpone a 5% MACE incidence by 12 months.Conclusions In SELECT-eligible first-time MI patients with overweight or obesity and no diabetes, the cardiovascular risk was substantial with 1 in 10 having a MACE event within 5 years after first-time MI. Based on the SELECT trial results, semaglutide may markedly postpone MACE incidence in these patients.
SN - 2772-963X
ER -